查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983708

免疫肿瘤市场：依治疗方法、适应症、治疗阶段和最终用户划分－2026-2032年全球市场预测

Immuno-Oncology Market by Therapy Type, Indication, Line Of Therapy, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，免疫肿瘤学市场价值将达到 64.9 亿美元，到 2026 年将成长至 71.6 亿美元，到 2032 年将达到 129.1 亿美元，复合年增长率为 10.30%。

主要市场统计数据
基准年 2025 64.9亿美元
预计年份：2026年 71.6亿美元
预测年份：2032年 129.1亿美元
复合年增长率 (%) 10.30%

本书整合了治疗方法、适应症和医疗保健服务的趋势，为不断演变的免疫肿瘤学领域的高级决策者提供了策略指南。

免疫肿瘤学的发展趋势正在重塑肿瘤学实践，透过机制上的突破性进展和新的治疗模式，改变临床医生、保险公司和研发人员应对癌症治疗的方式。本执行摘要整合了横断面趋势、细分市场洞察、监管和政策驱动因素以及可操作的建议，旨在为生物製药、临床研究和医疗服务领域的高级决策者提供有价值的资讯。

对重塑免疫肿瘤学发展和商业化的科学、製造、监管和市场进入因素进行全面分析。

由于科学、技术和商业性因素的融合，免疫肿瘤学领域正经历着变革性的转变，这些因素正在重塑竞争格局和病患治疗管道。细胞工程、新一代查核点调控、抗原鑑定和生产规模化的进步，使得更精准、更持久、更具联合疗效的治疗性介入成为可能。因此，治疗策略正从单一疗法转向整合疗法，将查核点抑制剂与疫苗、过继性细胞疗法、细胞激素调控或溶瘤平台结合，以增强抗肿瘤反应。

美国累积关税措施对免疫肿瘤学供应链、製造地和临床开发营运的策略影响。

关税的征收和贸易政策的变化正对免疫肿瘤领域的全球供应链和成本结构产生重大影响，尤其是在依赖跨境采购试剂、专用设备和契约製造的先进治疗方法。关税的累积趋势会影响企业生产基地的选址、供应商网路的建构方式，以及承销商和投资者为生产计划分配的风险溢价。对于需要复杂低温运输物流和一次性耗材的治疗方法，例如细胞疗法和DNA疫苗，关税导致的成本增加会对采购、批次放行计画和最终治疗定价产生连锁反应。

将治疗方法、临床适应症、临床环境和作用机制连结起来的详细細項分析，可指导产品组合优先排序和市场进入计划。

细分市场洞察揭示了每种治疗方法类型、适应症、最终用户、治疗线和作用机制的差异化竞争和证据需求。就治疗方法类型而言，癌症疫苗、细胞疗法、查核点抑制剂、细胞激素和溶瘤病毒各自遵循不同的研发路径。在癌症疫苗中，树突细胞疫苗、DNA疫苗和胜肽疫苗在个人化需求、生产复杂性和给药方法方面存在差异，这些差异会影响临床实验室设计和商业化策略。细胞疗法包括CAR-T疗法、NK细胞疗法和TCR-T疗法。随着CAR-T疗法细分为异体移植和自体移植，经营模式也随之分化。自体移植强调患者个体化的物流和临床调整，而异体移植则优先考虑规模化、库存管理和现货产品的供应。

对美洲、欧洲、中东、非洲和亚太市场的法规、报销、临床试验和生产製造进行区域策略洞察。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的监管管道、报销框架、临床试验受试者招募和製造地选择。在美洲，完善的法规结构和高密度的三级医疗中心支持了先进免疫疗法的快速普及，而商业化策略必须应对复杂的支付方环境，该环境强调价值验证和基于结果的合约。该地区的临床生态系统能够支持大规模临床试验，并促进产业界、学术机构和契约製造组织 (CMO) 之间的合作，从而支持有前景的候选药物的快速迭代开发和规模化生产。

本文檔展示了企业级竞争与合作策略，说明了创新公司和服务供应商如何在先进免疫肿瘤学领域取得突破。

免疫肿瘤学领域的关键公司层面趋势反映了创新者、成熟的肿瘤企业和专业契约製造服务供应商等不同企业所采取的多元化策略。领先的研发公司透过专有平台、联合治疗策略以及从早期发现到后期检验的整合式临床开发专案来脱颖而出。对于专注于细胞疗法的公司而言，投资于生产控制、疗效评估和供应伙伴关係对于加快产品上市速度和确保产品品质的稳定性至关重要。疫苗研发公司则优先考虑抗原发现、递送优化以及与伴随诊断的整合，以提高反应的可预测性。

经营团队采用的实用策略建议，旨在使科学创新与可製造性、偿还能力以及弹性供应链的实施保持一致。

产业领导者应采取一系列综合策略措施，在管控临床、营运和商业性风险的同时，加速专案成功。首先，应在研发早期阶段优先考虑平台的可扩展性和可製造性，以避免价值链后期出现代价高昂的重新设计。这包括投资于标准化的疗效测试、模组化的生产流程以及供应商多元化，以支持自体和异体性管道。其次，临床开发应与支付方的预期保持一致，并透过将比较性终点、健康经济学数据收集和真实世界数据（RWE）生成整合到关键项目中，促进产品上市后的报销谈判。

一种稳健的基于三角测量的调查方法，结合了关键相关人员的见解、透过二手文献进行的检验以及基于情境的供应链和政策分析。

本研究采用三角测量调查方法进行综合分析，该方法结合了对关键相关人员的访谈、对二手文献的分析以及透过用例和监管文件审查进行的交叉检验。为了了解实际情况、证据预期和推广障碍，我们对临床研究人员、生产专家、监管事务专业人员、支付方和医院药物采纳决策者进行结构化访谈，并将访谈作为主要资讯资讯来源。二级资讯来源包括同行评审的科学文献、监管指导文件和企业资讯披露，以检验机制趋势、临床结果和技术进步。

将免疫肿瘤学领域的创新转化为可持续的临床和商业性影响，需要将策略挑战和营运重点进行简洁的整合。

总之，免疫肿瘤学正处于一个转折点，科学知识、生产创新、政策趋势和商业策略在此交汇，共同决定哪些治疗方法能为患者带来持久的益处。从癌症疫苗和细胞激素到细胞疗法和查核点抑制剂，种类繁多的治疗方法既带来了复杂性，也带来了机会。要成功地将创新应用于临床实践，需要儘早将研发目标与可生产性、监管策略以及以支付方为中心的证据产生结合。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：免疫肿瘤市场：依治疗方法划分

  • 癌症疫苗
  • 细胞疗法
    • CAR-T疗法
      • 同种
      • 自有住房
    • NK细胞疗法
    • TCR-T疗法
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 细胞激素
  • 溶瘤病毒

第九章：免疫肿瘤市场：依适应症划分

  • 乳癌
    • HER2阳性乳癌
    • 三阴性乳癌
  • 结肠癌
  • 肺癌
    • 非小细胞肺癌
    • 小细胞肺癌
  • 淋巴瘤
  • 黑色素瘤
    • 皮肤黑色素瘤
    • 葡萄膜黑色素瘤

第十章：免疫肿瘤市场：依治疗阶段划分

  • 第 1 行
  • 从第四行开始
  • 第二行
  • 第三行

第十一章：免疫肿瘤市场：依最终用户划分

  • 学术机构
  • 癌症研究机构
  • 诊所
  • 医院

第十二章：免疫肿瘤市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：免疫肿瘤市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 免疫肿瘤市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国免疫肿瘤市场

第十六章：中国免疫肿瘤市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agenus Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Limited
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Johnson & Johnson
  • Juno Therapeutics, Inc.
  • Legend BIoTech Corporation
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-FF012EDC38BF

The Immuno-Oncology Market was valued at USD 6.49 billion in 2025 and is projected to grow to USD 7.16 billion in 2026, with a CAGR of 10.30%, reaching USD 12.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.49 billion
Estimated Year [2026] USD 7.16 billion
Forecast Year [2032] USD 12.91 billion
CAGR (%) 10.30%

Strategic orientation to the evolving immuno-oncology landscape integrating therapeutic modalities, indications, and care delivery dynamics for senior decision-makers

The immuno-oncology landscape continues to redefine oncology practice through mechanistic breakthroughs and new therapeutic paradigms that shift how clinicians, payers, and developers approach cancer treatment. This executive summary synthesizes cross-cutting trends, segmentation intelligence, regulatory and policy drivers, and actionable recommendations to inform senior decision-makers across biopharma, clinical research, and healthcare delivery organizations.

Over the past decade, immuno-oncology matured from proof-of-concept studies to mainstream standards of care for several indications, and the field now spans a wide range of modalities. Based on therapy type, the space comprises cancer vaccines, cell therapy, checkpoint inhibitors, cytokines, and oncolytic viruses. Within cancer vaccines, dendritic cell vaccines, DNA vaccines, and peptide vaccines each represent distinct development pathways and manufacturing requirements. Cell therapy includes CAR-T therapy, NK cell therapy, and TCR-T therapy, with CAR-T further divided into allogeneic and autologous approaches. Checkpoint inhibitors encompass CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, which continue to evolve through combination regimens and novel formats.

Indication-driven dynamics shape both clinical development priorities and commercial access strategies. The market spans breast cancer, colorectal cancer, lung cancer, lymphoma, and melanoma, with notable subsegments such as Her2-positive and triple-negative breast cancer, non-small cell lung cancer and small cell lung cancer, and cutaneous and uveal melanoma. End users range from academic institutes and cancer research institutes to clinics and hospitals, reflecting both centralized and decentralized models of care delivery. Line-of-therapy considerations span first line through fourth line or beyond, while mechanistic distinctions separate active immunotherapy from passive approaches; active immunotherapy includes cancer vaccines and cytokine-based therapies, and passive immunotherapy includes adoptive cell transfer, checkpoint inhibitors, and monoclonal antibodies, with adoptive cell transfer comprising CAR-T and TCR-T therapies.

This introduction frames the deeper insights that follow, highlighting the interplay between therapeutic innovation, regulatory pressures, reimbursement realities, and shifting supply chains. It is intended to equip executives with a clear orientation to the strategic levers that will determine competitive positioning and clinical impact over the coming years.

Comprehensive analysis of scientific, manufacturing, regulatory, and market-access forces that are reshaping immuno-oncology development and commercialization

The immuno-oncology sector is experiencing transformative shifts driven by converging scientific, technological, and commercial forces that are reshaping competition and patient pathways. Advances in cellular engineering, next-generation checkpoint modulation, antigen identification, and manufacturing scalability are enabling more precise, durable, and combinable interventions. As a result, therapeutic strategies are migrating from single-agent approaches to integrated regimens that pair checkpoint inhibitors with vaccines, adoptive cell therapies, cytokine modulation, or oncolytic platforms to amplify antitumor responses.

Concurrently, innovation in cell therapy formats-spanning autologous CAR-T constructs to off-the-shelf allogeneic CAR-T and NK cell therapies-reduces time-to-treatment and expands access beyond tertiary centers. The maturation of CAR-T and TCR-T research underscores an increasing focus on manufacturability, standardized potency assays, and closed-system production to support scale-up. At the same time, cancer vaccines are regaining traction as neoantigen discovery improves and DNA and peptide platforms become more adaptable to personalized approaches. Checkpoint inhibitor strategies are moving beyond broad PD-1/PD-L1 blockade to exploit combinatorial biology and bispecific constructs that modulate multiple immune axes.

Regulatory ecosystems and payer frameworks are also adapting to these innovations. Accelerated approval pathways and conditional reimbursement arrangements are being used to reconcile early clinical benefit with longer-term evidence generation, and value-based contracting is increasingly applied to high-cost cell and gene therapies. This shift demands more robust real-world evidence capabilities and post-market surveillance infrastructures. Supply chain resilience has risen on the executive agenda, particularly as advanced therapies depend on cold chain logistics, single-use components, and specialized manufacturing capabilities. Geopolitical factors and trade policies are introducing further complexity into sourcing and cross-border distribution.

Taken together, these transformative shifts require an integrated response that combines scientific rigor with commercial pragmatism. Organizations that align discovery priorities with pragmatic considerations-such as scalable manufacturing, differentiated clinical positioning, and adaptive reimbursement strategies-are better positioned to translate scientific breakthroughs into sustainable clinical impact and commercial success.

Strategic implications of cumulative United States tariff policy on immuno-oncology supply chains, manufacturing locations, and clinical development operations

The imposition of tariffs and trade policy changes has material implications for global supply chains and cost structures in immuno-oncology, particularly for advanced therapies that rely on cross-border sourcing of reagents, specialized equipment, and contract manufacturing capabilities. Cumulative tariff dynamics influence where organizations choose to locate production, how they structure supplier networks, and the risk premiums that underwriters and investors assign to manufacturing projects. For therapies such as cell therapy and DNA-based vaccines that require complex cold chain logistics and single-use materials, tariff-induced cost increases can cascade across procurement, batch release timelines, and final therapy pricing.

Manufacturers are responding through a mix of tactical and strategic actions. Tactical measures include re-negotiation of supplier contracts, hedging of foreign exchange exposures, and re-routing of logistics to minimize tariff exposure. Strategic responses emphasize regionalization of manufacturing capabilities, nearshoring of critical component production, and investments in modular, mobile, or decentralized manufacturing facilities that reduce cross-border movement of high-value biologicals. These strategic moves are often accompanied by tighter supplier qualification processes and a higher emphasis on dual sourcing for critical inputs to reduce single-point-of-failure risks.

Clinical trial operations are also affected as tariffs can increase the cost of investigational product distribution and device imports required for complex protocols. Sponsors are increasingly evaluating alternative trial designs and decentralized approaches to reduce the need for physical shipping of intermediate products across borders. In parallel, regulatory authorities may require additional quality and provenance documentation for products moved across tariff-impacted supply chains, increasing the administrative burden on sponsors and contract manufacturers.

In summary, cumulative tariff pressures accelerate the trend toward supply chain resilience and regional production capacity, and they elevate the importance of strategic procurement, flexible manufacturing architectures, and regulatory engagement. Organizations that proactively redesign their supply networks and incorporate tariff scenarios into long-range planning will mitigate operational disruption and preserve competitive flexibility.

In-depth segmentation intelligence linking therapeutic modalities, clinical indications, care settings, and mechanisms to guide portfolio prioritization and market access planning

Segmentation insights reveal differentiated competitive dynamics and evidence needs across therapy types, indications, end users, lines of therapy, and mechanisms of action. By therapy type, cancer vaccines, cell therapy, checkpoint inhibitors, cytokines, and oncolytic viruses each present distinct development pathways. Within cancer vaccines, dendritic cell vaccines, DNA vaccines, and peptide vaccines vary in personalization requirements, manufacturing complexity, and delivery modalities, which influence clinical trial designs and commercialization strategies. Cell therapy encompasses CAR-T therapy, NK cell therapy, and TCR-T therapy, and the split of CAR-T into allogeneic and autologous approaches creates divergent business models: autologous therapies emphasize patient-specific logistics and clinical coordination, while allogeneic therapies prioritize scale, inventory management, and off-the-shelf availability.

Indication-specific segmentation further refines opportunity and risk. Breast cancer, colorectal cancer, lung cancer, lymphoma, and melanoma have unique tumor microenvironments, prior therapy landscapes, and biomarker frameworks. Subsegments such as Her2-positive and triple-negative breast cancer, non-small cell lung cancer and small cell lung cancer, and cutaneous and uveal melanoma each require tailored development strategies, with different expectations for combination regimens and endpoints. End users-academic institutes, cancer research institutes, clinics, and hospitals-differ in their capacity to deliver complex immunotherapies, with tertiary cancer centers typically leading in adoption of cell therapies while community hospitals and clinics increasingly provide checkpoint inhibitor administration and vaccine-based interventions.

Line-of-therapy considerations are critical for positioning and value communication. First-line indications often demand robust comparative evidence and alignment with standard-of-care protocols, whereas later-line settings can accommodate accelerated pathways and biomarker-driven niche approvals. Mechanistic segmentation distinguishes active immunotherapy, which includes cancer vaccines and cytokine-based therapies, from passive immunotherapy, which comprises adoptive cell transfer, checkpoint inhibitors, and monoclonal antibodies. Within passive immunotherapy, adoptive cell transfer-encompassing CAR-T and TCR-T therapies-commands particular attention for its clinical complexity and potential curative outcomes in select populations.

Taken together, segmentation insights suggest that commercial success depends on aligning modality-specific strengths with indication-specific needs, optimizing delivery models for distinct end-user settings, and sequencing evidence generation to match line-of-therapy expectations. Organizations that integrate these segmentation layers into portfolio planning and market access strategies will increase the precision of their clinical pathways and the clarity of their value propositions.

Regional strategic insights on regulatory, reimbursement, clinical trial, and manufacturing considerations across Americas, EMEA, and Asia-Pacific markets

Regional dynamics shape regulatory pathways, reimbursement paradigms, clinical trial recruitment, and manufacturing footprint decisions across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established regulatory frameworks and a high concentration of tertiary care centers support rapid adoption of advanced immunotherapies, while commercialization strategies must navigate complex payer landscapes that emphasize value demonstration and outcomes-based contracting. Clinical ecosystems in this region enable large-scale trials and facilitate collaborations between industry, academic centers, and contract manufacturing organizations, which supports rapid iteration and scale-up for successful candidates.

Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement environment where regional agencies and national health systems influence market entry timing and pricing strategies. Centralized approvals can accelerate cross-border access within parts of Europe, but differential national reimbursement decisions and HTA requirements necessitate tailored evidence packages and credentialing initiatives. Stakeholders in this region increasingly focus on cost-effectiveness and real-world data to support access, and partnerships with regional manufacturing hubs can mitigate supply chain complexity.

Asia-Pacific reflects an expanding capacity for clinical development and manufacturing, with several markets prioritizing domestic biopharmaceutical innovation and regulatory modernization. Fast-growing trial populations, diversified payer models, and evolving regulatory pathways create opportunities for both multinational collaboration and local development. However, differences in standard-of-care, biomarker prevalence, and delivery infrastructure require nuanced market entry approaches. In response, companies are investing in regional manufacturing and distribution capabilities, local clinical partnerships, and market-specific evidence generation strategies to accelerate adoption while managing commercial risk.

Across regions, a common imperative is to align clinical development, regulatory engagement, and commercial planning with local health system realities. Firms that proactively design regional strategies-balancing centralized capabilities with localized execution-will better navigate heterogenous approval processes, reimbursement expectations, and patient access pathways.

Company-level competitive dynamics and partnership strategies demonstrating how innovators and service providers are enabling advanced immuno-oncology breakthroughs

Key company-level dynamics in immuno-oncology reflect diverse strategic approaches across innovators, established oncology franchises, and specialized contract manufacturing and service providers. Leading developers are differentiating through proprietary platforms, combination strategies, and integrated clinical development programs that span early discovery to late-stage validation. For companies focused on cell therapy, investments in manufacturing controls, potency assays, and supply chain partnerships are central to reducing time-to-patient and ensuring consistent product quality. Vaccine developers are prioritizing antigen discovery, delivery optimization, and companion diagnostic linkages to enhance response predictability.

Competitive positioning increasingly depends on collaborative networks and externalization of capabilities. Strategic partnerships between biotech innovators and larger oncology companies facilitate access to commercialization expertise, global distribution channels, and payer engagement resources. In parallel, alliances with academic institutions and cancer research institutes underpin translational research and rapid patient recruitment. Contract manufacturing organizations and technology providers that offer scalable, validated platforms for viral vectors, cell culture, and nucleic acid production are gaining importance as critical enablers of program advancement.

Corporate strategies also vary by risk appetite and portfolio breadth. Some companies pursue high-risk, high-reward assets with potentially transformative clinical profiles, while others focus on incremental improvements to existing standards of care to capture early market share and payer acceptance. Across these approaches, executive teams emphasize robust clinical operational capabilities, regulatory intelligence, and commercialization planning to bridge the gap between clinical proof and patient impact.

Ultimately, companies that combine deep scientific differentiation with pragmatic operational execution-investing in manufacturing resilience, regulatory dialogue, and payer-aligned evidence generation-are best placed to convert innovation into sustainable clinical and commercial outcomes.

Actionable strategic recommendations for leadership teams to align scientific innovation with manufacturability, reimbursement readiness, and resilient supply chain execution

Industry leaders should pursue an integrated set of strategic actions to accelerate program success while managing clinical, operational, and commercial risk. First, prioritize platform scalability and manufacturability during early development to avoid costly redesigns later in the value chain. This entails investing in standardized potency assays, modular manufacturing workflows, and supplier diversification to support both autologous and allogeneic pathways. Second, align clinical development with payer expectations by embedding comparative endpoints, health economics data collection, and real-world evidence generation into pivotal programs to streamline reimbursement conversations from launch.

Third, develop regionally nuanced market access strategies that reflect local regulatory requirements, HTA criteria, and delivery infrastructure. This requires early regulatory engagement, targeted evidence packages for different markets, and partnerships with regional clinical sites to ensure rapid adoption. Fourth, embrace combination-development frameworks that strategically pair checkpoint inhibitors, vaccines, cytokines, or cell therapies to address resistant tumor microenvironments; such programs should include biomarker-driven patient selection and adaptive trial designs to optimize signal detection.

Fifth, strengthen supply chain resilience through nearshoring options, dual sourcing of critical materials, and investments in cold chain and logistics capabilities to mitigate tariff and trade-related interruptions. Sixth, cultivate cross-sector partnerships with academic centers, technology platforms, and contract manufacturers to accelerate translational work and de-risk operational execution. Finally, ensure leadership teams integrate commercial planning early in development to harmonize clinical, regulatory, manufacturing, and market access strategies, thereby shortening time-to-value and improving patient reach.

Taken together, these recommendations form a cohesive blueprint for executives seeking to translate scientific innovation into durable clinical impact and commercial success while navigating an increasingly complex policy and operational environment.

Robust triangulated research methodology combining primary stakeholder insights, secondary literature validation, and scenario-based supply chain and policy analysis

This research synthesis draws on a triangulated methodology combining primary stakeholder interviews, secondary literature analysis, and cross-validation through case studies and regulatory document reviews. Primary inputs included structured interviews with clinical investigators, manufacturing experts, regulatory affairs professionals, payers, and hospital formulary decision-makers to capture operational realities, evidence expectations, and adoption barriers. Secondary sources encompassed peer-reviewed scientific literature, regulatory guidance documents, and company disclosures to validate mechanistic trends, clinical outcomes, and technology trajectories.

Analytical frameworks used in the research included segmentation by therapy type, indication, end user, line of therapy, and mechanism to map distinct evidence pathways and commercialization challenges. Scenario analyses examined the operational impact of tariff changes, supply chain disruption, and regional manufacturing shifts. Competitive landscaping incorporated public filings, clinical trial registries, and patent landscaping to assess differentiation at the platform level. Where appropriate, case studies of recent approvals and commercialization rollouts were used to illustrate translational best practices and pitfalls.

The approach emphasizes transparency and reproducibility: assumptions, data sources, and analytical choices were documented to facilitate client-driven sensitivity testing and bespoke adaptation. Limitations include the dynamic nature of regulatory and trade policy environments, which require ongoing monitoring, and the variability in local healthcare infrastructures that can affect transferability of specific operational models. Nevertheless, the methodology provides a robust foundation for strategic decision-making and can be extended through commissioned bespoke analyses focused on specific modalities, regions, or commercial scenarios.

Concise synthesis of strategic imperatives and operational priorities to convert immuno-oncology innovation into sustainable clinical and commercial impact

In conclusion, immuno-oncology is at an inflection point where scientific capability, manufacturing innovation, policy dynamics, and commercial strategy converge to determine which therapies will achieve durable patient impact. The diversity of modalities-from cancer vaccines and cytokines to cell therapies and checkpoint inhibitors-creates both complexity and opportunity. Successful translation of innovation into care requires early alignment of development objectives with manufacturability, regulatory strategy, and payer-focused evidence generation.

Organizations that proactively address supply chain resilience, regional regulatory heterogeneity, and the evolving expectations of payers and providers will be best positioned to scale transformative therapies. By integrating the segmentation, regional, and company-level insights presented here, executives can prioritize investments that maximize clinical benefit while managing operational risk. The recommendations provided offer a pragmatic roadmap to guide portfolio decisions and commercialization planning as the field continues to evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-Oncology Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. Cell Therapy
    • 8.2.1. CAR-T Therapy
      • 8.2.1.1. Allogeneic
      • 8.2.1.2. Autologous
    • 8.2.2. NK Cell Therapy
    • 8.2.3. TCR-T Therapy
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. CTLA-4 Inhibitors
    • 8.3.2. PD-1 Inhibitors
    • 8.3.3. PD-L1 Inhibitors
  • 8.4. Cytokines
  • 8.5. Oncolytic Viruses

9. Immuno-Oncology Market, by Indication

  • 9.1. Breast Cancer
    • 9.1.1. Her2-Positive Breast Cancer
    • 9.1.2. Triple-Negative Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
    • 9.3.1. Nsclc
    • 9.3.2. Small Cell Lung Cancer
  • 9.4. Lymphoma
  • 9.5. Melanoma
    • 9.5.1. Cutaneous Melanoma
    • 9.5.2. Uveal Melanoma

10. Immuno-Oncology Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line Or Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Immuno-Oncology Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Cancer Research Institutes
  • 11.3. Clinics
  • 11.4. Hospitals

12. Immuno-Oncology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Immuno-Oncology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immuno-Oncology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Immuno-Oncology Market

16. China Immuno-Oncology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agenus Inc.
  • 17.6. Allogene Therapeutics, Inc.
  • 17.7. Amgen Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Autolus Limited
  • 17.10. BeiGene, Ltd.
  • 17.11. BioNTech SE
  • 17.12. Bristol-Myers Squibb Company
  • 17.13. Celgene Corporation
  • 17.14. Eli Lilly and Company
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Immutep Ltd.
  • 17.18. Johnson & Johnson
  • 17.19. Juno Therapeutics, Inc.
  • 17.20. Legend Biotech Corporation
  • 17.21. Merck & Co., Inc.
  • 17.22. Moderna, Inc.
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Regeneron Pharmaceuticals, Inc.
  • 17.26. Roche Holding AG
  • 17.27. Sanofi S.A.
  • 17.28. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 218. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 251. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 261. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 262. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA IMMUNO-ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)